- Home
- EVMN vs SDHY Comparison
EVMN vs SDHY Comparison
Compare EVMN & SDHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVMN | SDHY |
|---|---|---|
| Founded | 2020 | 2020 |
| Country | United States | United States |
| Employees | 48 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 475.8M | 404.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EVMN | SDHY |
|---|---|---|
| Price | $11.40 | $16.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $43.88 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 57.3K |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.46% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $15.07 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.15 | $15.55 |
| 52 Week High | $33.20 | $17.18 |
Technical Indicators
Market Signals| Indicator | EVMN | SDHY |
|---|---|---|
| Relative Strength Index (RSI) | 32.78 | 49.62 |
| Support Level | N/A | $15.87 |
| Resistance Level | $21.21 | $16.25 |
| Average True Range (ATR) | 1.06 | 0.18 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 9.46 | 33.96 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It mainly invests in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments (including derivatives) with similar economic characteristics.